TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01888276

Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of word generation and of motivation
Description: Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The test of Stroop that assesses selective attention~During the session 2:~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The task of the casino (Iowa Gambling Test)~* The task of landing~* The test of Stroop

Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of word generation and of motivation
Description: Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The test of Stroop that assesses selective attention~During the session 2:~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The task of the casino (Iowa Gambling Test)~* The task of landing~* The test of Stroop
Study: NCT03304223

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]FB-IL2 PET scan
Description: \[18F\]FB-IL2 PET scan procedure
Study: NCT01032213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Group S received the same volume of isotonic saline as same method.
Study: NCT03336580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX004
Description: PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)
Study: NCT03039985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crowns (Prettau®)
Description: Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crowns (Prettau®)
Description: Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lithium disilicate crowns (IPSe.max®)
Description: lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lithium disilicate crowns (IPSe.max®)
Description: lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
Study: NCT03701308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study: NCT03247998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conscious Sedation with Remifentanil
Description: Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
Study: NCT01686503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
Description: Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
Description: Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
Description: Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
Description: Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
Study: NCT01221298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets
Study: NCT03701308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Given IV
Study: NCT00790660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT00191152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2, intravenous (IV), every 21 days until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2, intravenous (IV), every 21 days until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
Study: NCT02331121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family First Aid Online Training
Description: Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-only Online Training
Description: Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
Study: NCT04813874

Intervention type: DRUG
Intervention: Nitrous Oxide
Description: Nitrous Oxide Inhalational Agent

Intervention type: DRUG
Intervention: Nitrous Oxide
Description: Nitrous Oxide Inhalational Agent

Intervention type: PROCEDURE
Intervention: Neuraxial analgesia
Description: Epidural Labor Analgesia Placement
Study: NCT02656342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Predicted to enhance stabilization of the effects of concentrated exposure treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Predicted to enhance stabilization of the effects of concentrated exposure treatment
Study: NCT03277079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statin + ezetimibe
Description: Combination of two drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statin + ezetimibe
Description: Combination of two drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statin + ezetimibe + Nutraceuticals
Description: Combination of two grus plus nutraceuticals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statin + ezetimibe + Nutraceuticals
Description: Combination of two grus plus nutraceuticals
Study: NCT04099771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine infusion
Study: NCT01997385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: KAPD-C
Description: KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KAPD-A
Description: KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
Study: NCT03053765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training in IPT
Description: Follow-up training in IPT to determine which best enhances fidelity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training in IPT
Description: Follow-up training in IPT to determine which best enhances fidelity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training in IPT
Description: Follow-up training in IPT to determine which best enhances fidelity
Study: NCT03695276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PushCon Model
Description: Pulmonary specialist consultation facilitated by a trained health coach, who will gather information from the patient and medical record prior to the consultation and will using health coaching skills to support implementation of recommended care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The standard of care, which usually means management within primary care.
Study: NCT04577352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vatiquinone
Description: Vatiquinone will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatiquinone
Description: Vatiquinone will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered per schedule specified in the arm.
Study: NCT02656342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Predicted to have no enhancing effect
Study: NCT03430570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet TRAC Emotion Regulation Intervention
Description: The intervention focuses on developmentally appropriate strategies for emotion regulation during difficult situations, particularly those related to risk, using 3 primary groups of strategies identified during qualitative work in Project TRAC (R34 MH078750): 1) getting away (physically or cognitively) from triggers for strong emotions, 2) releasing emotional energy in healthy ways (physically or verbally) or 3) changing cognitions and appraisals about emotional triggers. Using strategies effective in TRAC, teens will engage in games to practice and apply strategies to risk scenarios, as well as personalize content learned.
Study: NCT01520714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead
Description: 1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead
Description: 1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
Study: NCT01213771

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Preoperative preparation 2010
Description: Preoperative optimisation Supportive care LEAN in patient pathways
Study: NCT04331379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Elevator
Description: A device aiming to elevate the clefted nostril extraorally and fixed on the forehead.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taping Alone
Description: Horizontal tape alone.
Study: NCT01774539

Intervention type: OTHER
Intervention: Diffusion MRI
Description: Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
Study: NCT01392495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 200 mg or 400 mg qd
Study: NCT03299335

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: assay of CPK and anti-cN-1A antibodies

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: assay of CPK and anti-cN-1A antibodies

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: assay of CPK and anti-cN-1A antibodies
Study: NCT04017468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
Study: NCT04506710

Intervention type: BEHAVIORAL
Intervention: Audio recording of the counseling conversation
Description: The patient will have an audio-recorded counseling conversation. Audio recording will be carried out using a portable recorder ZOOM H2n. The audio recordings of the counseling conversations will be performed by the health workers selected to participate in the study.
Study: NCT01221298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: capsules
Study: NCT04252807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm
Description: In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
Study: NCT02517138

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: Measurements of eye movements and perception
Study: NCT01029197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and exposure therapy for PTSD
Description: The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
Study: NCT02968875

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training
Description: 40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic education meetings
Description: Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
Study: NCT00984633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Org 9426)
Description: 0.6 mg/kg injection intubation dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Org 9426)
Description: 0.6 mg/kg injection intubation dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Org 9426)
Description: 0.9 mg/kg injection intubation dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Org 9426)
Description: 0.9 mg/kg injection intubation dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 0.5-2.0% intravenous maintenance anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 0.5-2.0% intravenous maintenance anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 4-10 mg/kg/hr maintenance anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 4-10 mg/kg/hr maintenance anesthesia
Study: NCT04642066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Description: Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No cold water immersion
Description: People without cold water immersion
Study: NCT00940511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated care
Study: NCT00930787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strattice Reconstructive Tissue Matrix (Hernia Repair)
Description: Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proceed Surgical Mesh (Hernia repair)
Description: Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
Study: NCT02316132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stress
Description: Corticotropin-Releasing Hormone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Saline 0.9%
Study: NCT04252807

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
Study: NCT03101670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgotinib
Description: one filgotinib oral tablet q.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: one placebo oral tablet q.d.
Study: NCT00933946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
Study: NCT04783168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Install and use Fitbit app
Study: NCT03549624

Intervention type: OTHER
Intervention: Standardised protocol for the perioperative management in patients in need of an acute laparotomy
Description: A standardised protocol for the perioperative management of patients including early start of antibiotics and swift surgical intervention as well as an emphasis on repeated monitoring of physiological parameters pre- and post-operatively.